Patents
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
02/2003
02/05/2003CN1395581A Recombinant antibodies to human IL-1 beta
02/05/2003CN1395577A Ethanol solvate of (-)-cis-2-2(2-chlorophenyl)-5, 7-dihydroxy-8[4R-(3S-hydroxy-1-1methyl) piperidinyl]-4H-1-benzopyran-4-one
02/05/2003CN1395574A Food product and producing method
02/05/2003CN1395568A 1,2-diaryl benzimidazole derivative for treating illnesses associated with microglia activation
02/05/2003CN1395566A Corticotropin releasing factor antagonists
02/05/2003CN1395565A Indole derivatives as MCP-1 receptor antagonists
02/05/2003CN1395564A Indole derivatives as MCP-1 receptor antagonists
02/05/2003CN1395556A Monohydrate of cis-lithium-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl] cyclohexanecarboxylate
02/05/2003CN1394855A Substituted heterocyclic compound
02/05/2003CN1394642A Chinese medicine for curing rheumatoid arthritis
02/05/2003CN1394637A Powder preparation for stopping pain and dispersing swelling
02/05/2003CN1394612A Antler gelatin medicated liquor for curing sciatica and its preparation method
02/05/2003CN1394597A Process for preparing powder preparation
02/05/2003CN1100777C N-heterocyclic derivatives as NOS inhibitor
02/05/2003CN1100773C Benzofran carboxamides and sulphonamides
02/05/2003CN1100748C Inhibition of matrix metalloproteases by 2-substituted-4-(4-substituted phenyl)-4-oxobutyric acids
02/05/2003CN1100560C Production process for medicinal liquor
02/05/2003CN1100556C Shujinhuoluoye Chinese medicine liquid for curing rheumatism and its preparing method
02/05/2003CN1100540C Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
02/05/2003CN1100538C Lotion
02/04/2003US6515173 Inhibitors of the ICE/ced-3 family of cysteine proteases
02/04/2003US6515124 Dehydroamino acids
02/04/2003US6515027 Substituted benzanilides as CCR5 receptors ligands, antiinflammatory agents and antiviral agents
02/04/2003US6515016 Treating or preventing multiple sclerosis, by administering an antimicrotubule agent; treating various other inflammatory diseases
02/04/2003US6515005 Substituted azole derivatives as inhibitors of corticotropin releasing factor
02/04/2003US6515004 Useful in the treatment of Alzheimer's disease, chemotherapy-induced alopecia, and cardiovascular disease
02/04/2003US6515003 Useful in the treatment of diseases related to lipid and carbohydrate metabolism
02/04/2003US6515002 Compounds and compositions for treating C1s-mediated diseases and conditions
02/04/2003US6514985 Induce the biosynthesis of cytokines such as interferon and tumor necrosis factor; exhibit antiviral and antitumor properties
02/04/2003US6514977 For treating p38 kinase mediated disorders
02/04/2003US6514975 Anti-inflammatory piperazinyl-benzyl-tetrazole derivatives and intermediates thereof
02/04/2003US6514970 Urotensin-II receptor antagonists
02/04/2003US6514964 Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors
02/04/2003US6514960 Use of bismuth subgallate in inhibition of production of nitric oxide synthase
02/04/2003US6514952 For the treatment and prophylaxis of diseases which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration such as rheumatoid arthritis or allergic disorders
02/04/2003US6514745 Oncoprotein protein kinase
02/04/2003US6514497 Inhibition of LERK-2-mediated cell adhesion
02/04/2003US6514491 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol)
02/03/2003WO2002016312A2 Novel compounds inhibiting factor xa activity
02/03/2003CA2418283A1 Novel compounds inhibiting factor xa activity
01/2003
01/31/2003WO2002012338A2 Screening method
01/31/2003CA2417972A1 Screening method
01/30/2003WO2003008595A2 Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression
01/30/2003WO2003008579A2 Polynucleotides expressed in dendritic cells and polypeptides encoded thereby
01/30/2003WO2003008576A2 Synthetic double stranded oligonucleotides for targeted inhibition of gene expression
01/30/2003WO2003008574A1 Mutations in ion channels
01/30/2003WO2003008480A1 Positively charged amphiphilic block copolymer as drug carrier and complex thereof with negatively charged drug
01/30/2003WO2003008457A2 Polysaccharidic esters of retinoic acid
01/30/2003WO2003008452A2 Bispecific monoclonal antibodies to il-12 and il-18 receptors
01/30/2003WO2003008444A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
01/30/2003WO2003008443A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
01/30/2003WO2003008425A1 Novel bisphosphonate derivatives, their preparation methods and uses
01/30/2003WO2003008422A1 Chemical compounds
01/30/2003WO2003008414A1 Chemical compounds
01/30/2003WO2003008413A1 Imidazopyridinones as p38 map kinase inhibitors
01/30/2003WO2003008412A2 Hetero-bicyclic crf antagonists
01/30/2003WO2003008410A2 Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression
01/30/2003WO2003008409A1 Quinoline derivatives and their use as tyrosine kinase inhibitors
01/30/2003WO2003008407A2 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
01/30/2003WO2003008396A1 Optically active oxazine derivative
01/30/2003WO2003008392A1 4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1, 2, 4) triazin-5-one derivatives having a pde-iv inhibiting and tnf-antagonistic effect for the treatment of cardiac diseases and allergies
01/30/2003WO2003008388A1 I-form crystal of n-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl}-n'-propylurea and process for producing the same
01/30/2003WO2003008384A1 Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands
01/30/2003WO2003008377A1 Prostaglandin analogues_as ep4 receptor agonists
01/30/2003WO2003008374A1 Inhibitors of the ice/ced-3 family of cysteine proteases
01/30/2003WO2003007993A1 Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor
01/30/2003WO2003007984A1 Uv cross-linkable melt adhesives containing stabilizers
01/30/2003WO2003007978A1 Alpha-fetoprotein peptides and uses thereof
01/30/2003WO2003007971A1 Improved heteropolymer complexes and methods for their use
01/30/2003WO2003007958A1 Tetrahydroquinoxalines acting as bradykinin antagonists
01/30/2003WO2003007954A2 Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
01/30/2003WO2003007950A1 (pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid x receptor modulators
01/30/2003WO2003007933A1 Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders
01/30/2003WO2003007930A2 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
01/30/2003WO2003007876A2 N-fatty acid-amino acid conjugates and therapeutic uses
01/30/2003WO2003007875A2 Compounds with analgesic, antipyretic and/or anti-inflammatory activity
01/30/2003WO2003007794A2 Invasion complex and methods of targeting
01/30/2003WO2003007689A2 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids
01/30/2003WO2003007686A2 Use of copper chelators to inhibit the inactivation of protein c
01/30/2003WO2002088079A3 Dual inhibitors of pde 7 and pde 4
01/30/2003WO2002069984A3 Use of hyaluronic acid uronides for the treatment of inflammatory processes
01/30/2003WO2002069945A3 Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors
01/30/2003WO2002066002A3 Pharmaceutical formulation
01/30/2003WO2002064160A8 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
01/30/2003WO2002051435A3 New therapeutic uses of smr1 peptides
01/30/2003WO2002048180A3 Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic medicament
01/30/2003WO2002034243A3 Method for the treatment of neurological and neuropsychological disorders
01/30/2003WO2002034242A3 Method for the treatment of neurological and neuropsychological disorders
01/30/2003WO2002018583A3 Modified polypeptides stabilized in a desired conformation and methods for producing same
01/30/2003WO2002016567A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
01/30/2003WO2002014536A3 Odulating multiple lineage kinase proteins
01/30/2003WO2002002634A3 Human extracellular matrix and cell adhesion polypeptides
01/30/2003WO2001091792A9 Anti-adhesion molecule antibody to treat inflammation and cancer by inducing the idiotypic network
01/30/2003WO2001090359A3 G-protein coupled receptors
01/30/2003US20030023337 Manufacturing method
01/30/2003US20030023104 For prolonging or altering the activity of a compound which is a member of the chlorambucil family
01/30/2003US20030023100 For therapy of inflammatory and allergic reactions, drug or alcohol abuse, diarrhoea, gastritis, ulcers, cardiovascular diseases, urinary incontinence, depressions, states of shock, migranes, narcolepsy, overweight, asthma, glaucoma, etc.
01/30/2003US20030023038 For therapy of undesired cell proliferation; for stimulation and inhibition of lymphocytes
01/30/2003US20030022938 N-fatty acid-amino acid conjugates and therapeutic uses
01/30/2003US20030022934 For therapy and prophylaxis of pain and/or neurodegenerative disorders